Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2023012539
Abstract: Key Point • The addition of daratumumab to the VCD chemotherapy backbone provides deeper hematological responses and improved PFS. read more here.
Keywords: cyclophosphamide bortezomib; dexamethasone transplant; daratumumab cyclophosphamide; ineligible myeloma ... See more keywords